Does bleeding affect patient‐reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review

Does bleeding affect patient‐reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review

Background Relatively minor bleeding (e.g., bruising and/or petechiae) may cause patient distress. This systematic review's objective was to assess whether bleeding affects health‐related quality of life (HRQoL) or illness perceptions or representations (IPs) in patients with hematologic malign...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Estcourt, L, Pinchon, D, Symington, E, Kelly, A, Doree, C, Brunskill, S, Glidewell, L, Stanworth, S
Format:	Journal article
Język:	English
Wydane:	Wiley 2014

Podobne zapisy

Is sepsis a risk factor for bleeding in adults with hematologic malignancies?
od: Estcourt, L, i wsp.
Wydane: (2017)

Risk of bleeding and use of platelet transfusions in patients with hematological malignancies: recurrent event analysis
od: Stanworth, S, i wsp.
Wydane: (2015)

Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological malignancies (Review).
od: Wardrop, D, i wsp.
Wydane: (2013)

Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial.
od: Stanworth, S, i wsp.
Wydane: (2014)

Observational study of alternative platelet parameters to predict bleeding risk in patients with hematological malignancies (ATHENA study)
od: Estcourt, L, i wsp.
Wydane: (2013)

Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: A subgroup analysis of a randomized trial (CME)
od: Stanworth, S, i wsp.
Wydane: (2014)

Anti-fibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Protocol)
od: Wardrop, D, i wsp.
Wydane: (2016)

Pathogen-reduced platelets for the prevention of bleeding (protocol)
od: Butler, C, i wsp.
Wydane: (2011)

Pathogen-reduced platelets for the prevention of bleeding.
od: Butler, C, i wsp.
Wydane: (2013)

Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding.
od: Stanworth, S, i wsp.
Wydane: (2006)

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
od: Estcourt, L, i wsp.
Wydane: (2016)

Pathogen-reduced platelets for the prevention of bleeding (Review)
od: Butler, C, i wsp.
Wydane: (2013)

Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non-cardiac surgery or invasive procedures
od: Huber, J, i wsp.
Wydane: (2019)

Can we be certain that storage duration of transfused red blood cells does not affect patient outcomes?
od: Trivella, M, i wsp.
Wydane: (2019)

Platelet transfusions for patients with haematological malignancies: who needs them?
od: Estcourt, L, i wsp.
Wydane: (2011)

Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- The ATHENA study
od: Estcourt, L, i wsp.
Wydane: (2014)

Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
od: Estcourt, L, i wsp.
Wydane: (2012)

Transfusion Thresholds in Hematologic Malignancy Receiving Intensive Therapies - Risk of bias assessment
od: Estcourt, L
Wydane: (2023)

Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA study.
od: Estcourt, L, i wsp.
Wydane: (2014)

Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies‐ The ATHENA study
od: Estcourt, L, i wsp.
Wydane: (2014)

Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non‐cardiac surgery or invasive procedures
od: Huber, J, i wsp.
Wydane: (2018)

Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation
od: Estcourt, L, i wsp.
Wydane: (2014)

Hematologic malignancies : myelodysplastic syndromes /
od: Deeg, H. Joachim (Hans Joachim), 1945-
Wydane: (2006)

Different platelet count thresholds to guide use of prophylactic platelet transfusions for patients with hematological disorders after myelosuppressive chemotherapy or stem cell transplantation
od: Estcourt, L, i wsp.
Wydane: (2016)

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation (Protocol).
od: Estcourt, L, i wsp.
Wydane: (2014)

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation (protocol)
od: Estcourt, L, i wsp.
Wydane: (2014)

Pathogen-reduced platelets for the prevention of bleeding (Review)
od: Estcourt, L, i wsp.
Wydane: (2017)

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
od: Crighton, GL, i wsp.
Wydane: (2015)

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders
od: Gu, Y, i wsp.
Wydane: (2015)

Intracranial hemorrhage in patients with haematological malignancy, a nested case-control study
od: Estcourt, L, i wsp.
Wydane: (2017)

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders (Protocol)
od: Gu, Y, i wsp.
Wydane: (2015)

Persistent malignant stem cells in del(5q) myelodysplasia in remission.
od: Tehranchi, R, i wsp.
Wydane: (2010)

Risk factors for haemorrhage in patients with haematological malignancies
od: Estcourt, LJ
Wydane: (2014)

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation (protocol)
od: Estcourt, L, i wsp.
Wydane: (2014)

Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
od: Craddock, C, i wsp.
Wydane: (2016)

The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions.
od: Estcourt, L, i wsp.
Wydane: (2013)

The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions
od: Estcourt, L, i wsp.
Wydane: (2013)

The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions
od: Estcourt, L, i wsp.
Wydane: (2013)

Modeling hematologic malignancies and their treatment in humanized mice
od: Leskov, Ilya, Ph. D. Massachusetts Institute of Technology
Wydane: (2011)

Analysis of Current Patterns of Utilisation of Platelet Transfusion Components in Hematology Patients
od: Estcourt, L, i wsp.
Wydane: (2011)